Objective: To study the effect of edaravone dexamphetamine injection with concentrated solution combined with eurekulin in acute cerebral infarction. Methods: 94 patients with acute cerebral infarction in our hospital were included from October 2021 to October 2024, and were divided into group B (n=47, eurekulin) and group A (n=47, edaravone dextran camphenol added on the basis of group B) according to the method of randomized numerical table. The efficacy, adverse effects, Neurological Impairment Hypothesis Scale (NIHSS) scores, Measured Mental State Examination (MMSE) scores, neurofactors [neuron-specific enolase (NSE), brain-derived nerve growth factor (BDNF), β-amyloid 1-42 (Aβ1-42)], inflammatory factors [C-reactive protein (CRP), interleukin-8 (IL-8)], and inflammation factors [C-reactive protein (CRP), interleukin-8 (IL-8)] were observed in the two groups. (IL-8)] levels, Barthel Index (BI) scores, and General Quality of Life Inventory (GQOLI74) scores. Results: The total effective rate of treatment in group A was 93.62% (44/47) higher than that in group B, which was 72.34% (34/47) (P < 0.05); compared with group B, the NIHSS score was lower, and the MMSE score, BI score, and GQOLI74 score were higher in group A after treatment (P < 0.05); after treatment, the levels of NSE, Aβ1-42, CRP, and IL-8 were lower, and the levels of BDNF were lower, and the levels of BDNF were lower, and the levels of BDNF were lower, than those of group B. group A was lower and BDNF level was higher than group B (P < 0.05); there was no significant difference in the comparison of the incidence of adverse reactions between the two groups (P > 0.05).Conclusion: Edaravone dexamethasone concentrated solution for injection combined with eurekulin is effective in patients with acute cerebral infarction, which can reduce neurological deficits, improve cognitive function, regulate the level of neurofactors, reduce the symptoms of inflammation, and improve the quality of life, and has a better safety profile.